Global Brain has invested in EditForce, Inc. (EditForce), a company developing unique DNA / RNA editing technology to bring innovation to various industries, through its GB-VII Growth Fund Investment Limited Partnership (GB-VII) and its KDDI Open Innovation Fund III (KOIF III).
EditForce has developed DNA/RNA editing tools by integrating pentatricopeptide repeat (PPR) proteins with various enzymes. As opposed to other genome editing technology, this technology enables the editing of not only DNA sequences but also RNA sequences. Currently, EditForce has focused on the field of pharmaceuticals and has grown through business alliances with multiple pharmaceutical companies.
Global Brain has decided to invest in EditForce, thinking highly of their unique DNA / RNA editing technology and strong management team. Global Brain will continue leveraging its resources to assist EditForce in fast-growing on the field of pharmaceuticals and expanding their business into new field such as agriculture and chemical.
About EditForce, Inc.
- Location
- 4F Fukuoka Tenjin Fukoku Seimei Bldg. 1-9-17, Tenjin, Chuo-ku, Fukuoka
- Representative
- Takashi Ono
- Founded
- May 15, 2015
- URL
- https://www.editforce.co.jp/
About GB-VII
- Name
- GB-VII Growth Fund Investment Limited Partnership
- General Partner
- Global Brain Corporation
About KOIF III
- Name
- KDDI Open Innovation Fund III
- General Partner
- Global Brain Corporation
- Fund Size
- 20 Billion JPY
About Global Brain
- Location
- Tokyo, Japan
- Representative
- Yasuhiko Yurimoto
- Founded
- January, 1998